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Introduction: We investigated the single-nucleotide polymorphism
C-938A in the apoptotic gene BCL-2 to assess the potential impact
as a genetic marker for response to chemotherapy and outcome
prediction in small cell lung cancer (SCLC) patients. Such a marker
might help optimize lung cancer treatment in a tailored approach.
Methods: DNA derived from peripheral blood lymphocytes of 188
Caucasian SCLC patients treated at the Thoraxklinik Heidelberg
was genotyped. Chemotherapy response, time to progression (TTP),
and overall survival (OS) were evaluated using multivariable regres-
sion (unconditional logistic for response and Cox proportional
hazard for TTP and OS) with odds ratios and hazard ratios (HRs)
and their 95% confidence intervals (CIs) as quantitative outcome
measures, respectively.
Results: Small cell lung cancer patients carrying the BCL-2 -938CC
genotype showed significantly worse TTP than patients carrying the
BCL-2 -938AA genotype (HR  1.86; 95% CI  1.10–3.13, p 
0.021). The same adverse effect was shown for OS (HR  2.38;
95% CI  1.38–4.12, p  0.002). Also, patients with limited
disease (HR  2.57; 95% CI  1.18–5.60, p  0.017) showed
worse OS with the BCL-2 -938CC genotype.
Conclusion: BCL-2 -938CC genotype shows significantly worse
outcome in small cell lung cancer patients. This genetic marker
might particularly impact on treatment strategies using BCL-2
antisense approaches.
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Small cell lung cancer (SCLC) is characterized by a goodinitial response to chemotherapy. Unfortunately, treat-
ment outcome is often poor because of early relapse. Patients
with limited disease are mostly treated with a combination
chemotherapy of platinum and etoposide in conjunction with
radiotherapy of the chest. Those with extensive disease
mostly receive platinum- or anthracycline-containing drug
combinations. Median survival times are in the range of 18 to
20 months for limited disease and 9 to 12 months for
extensive disease.1
One effect of cancer chemotherapeutics is to induce
apoptosis via DNA damage. Hence, treatment efficacy not
only depends on the amount of DNA damage but also on the
capacity of the cell to undergo apoptosis thereafter. A lower
ability of apoptosis induction not only increases the risk to
develop cancer but also promotes failure to achieve chemo-
therapy response because of drug resistance.2 Apoptosis can
be induced by an intrinsic mitochondrial-induced and by an
extrinsic receptor-mediated pathway. Although DNA damage
induced by many chemotherapeutics mainly triggers mito-
chondrial-induced apoptosis, there is still some crosstalk
between the two pathways. One important step in the intrinsic
apoptotic pathway is the efflux of cytochrome c out of the
mitochondria which then further triggers the apoptotic cas-
cade. Proapoptotic and antiapoptotic members of the BCL-2
family regulate this efflux,3 where BCL-2 acts as an antiapop-
totic regulator.
Current approaches targeting BCL-2 attempt to further
improve treatment outcome in SCLC. The study by Rudin
et al.4 investigated the effect of the BCL-2 antisense oligo-
nucleotide “oblimersen” in combination with a chemotherapy
of etoposide and platinum on toxicity and outcome. No
significant effect of “oblimersen” was detected, possibly due
to insufficient suppression of BCL-2. It is likely that different
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agents will be tested on their ability to suppress BCL-2 and
their influence on survival in SCLC patients.5,6 It would be
interesting to distinguish, before treatment, those patients
who have a high chance of benefiting from such an approach
or those who do not, on the basis of particular host or tumor
characteristics.
Single-nucleotide polymorphisms (SNPs) in BCL-2
could help to characterize those subgroups. SNPs in general
account for more than 90% of the genetic variation in the
human genome. Many SNPs are known to be involved in
pathways such as apoptosis, which are important for cancer
development and chemotherapy resistance.7 The A-allele of
the investigated polymorphism C-938A has been associated
with increased BCL-2 expression.8
The aim of this project was to identify whether the SNP
C-938A in the apoptotic gene BCL-2 could serve as a marker
for chemotherapy response and outcome in SCLC patients.
Such a marker, if it exists, would allow development of
individualized therapy regimens.9
Because this functional polymorphism is located in a
key apoptotic gene, we postulated that it might result in
different levels of apoptosis induced by chemotherapy regi-
mens. Therefore, the aim of this study was to investigate
whether this BCL-2 polymorphism has an effect on early
response to chemotherapy, overall survival (OS), and time to
progression (TTP).
PATIENTS AND METHODS
Study Population, Response Assessment, and
Survival Calculation
A total of 188 patients diagnosed with SCLC and
treated with first-line chemotherapy between 1998 and 2007
at the Thoraxklinik Heidelberg were analyzed. Written in-
formed consent was obtained from all participants. The study
was approved by the ethics committee of the University of
Heidelberg. Response to chemotherapy was assessed by com-
parison of baseline with follow-up imaging after the second
(n2  174) or third (n3  14) cycle of chemotherapy.
Response Evaluating Criteria in Solid Tumors (RECIST 1.0)
were applied in a separate retrospective read by an experi-
enced chest radiologist (S.T. or C.P.H.).10 Patients were
categorized into responder (complete response and partial
response) and nonresponder (stable disease and progressive
disease). Assessment was performed on the basis of pairs of
spiral computed tomography (CT) scan for 24 patients. A
total of 164 patients were assessed on the basis of paired chest
radiographs (two planes, erect).
TTP was calculated from the start of treatment until
documentation of the first date of progression or the last date of
follow-up. The end point TTP was assessed completely by CT.
OS was calculated from the start of treatment until
death or the last date of follow-up.
Limited disease patients were treated with a first-line
chemotherapy in combination with thoracic radiation. One
patient with limited disease did not receive the planned
radiotherapy because of his restricted lung function.
Extensive disease patients were treated by chemother-
apy alone, except eight patients, who received chemotherapy
and radiotherapy on an individually based treatment decision
(younger age; favorable tumor response).
Genotyping
Peripheral blood samples were collected before chemo-
therapy. DNA was isolated from buffy coat using the
QIAamp DNA blood midi kit. Genotyping was performed by
polymerase chain reaction followed by fluorescence-based
melting curve analysis (LightCycler 480, Roche Diagonstics
GmbH, Mannheim, Germany). The newly developed Light-
Cycler method was validated by repeating the genotyping for
200 samples by restriction fragment length polymorphism
analysis. In addition, as a quality assurance measure, 10% of
the samples were repeated blindly with 100% concordance. A
negative control and positive controls were always run as
standard controls.
For the polymerase chain reaction followed by melting
curve analysis, the following primers and probes were used:
forward primer: GCTTCACGCCTCACCAG, reverse primer:
TCCAGCAGCTTTTCGGAA, sensor: LCRed640-CCTTCA-
TCGTCCCCTCTCC, anchor: CCTGCCTCCGTCCCCGGC-FL
(LCRed640: fluorescence dye, FL: fluorescein).
The cycling conditions were as follows: initial denatur-
ation at 95°C for 2 minutes followed by 40 cycles consisting
of denaturation at 95°C for 2 seconds, 60°C annealing tem-
perature for 5 seconds, and elongation at 72°C for 6 seconds.
Melting curve analyses were performed with an initial dena-
turation at 95°C for 1 minute, 1 minute at 40°C followed by
slow heating of the samples to 80°C and permanent fluores-
cence detection.
Statistical Analysis
Genotype frequencies were compared in responders
and nonresponders. Odds ratios (ORs) and 95% confidence
intervals (CIs) for the risk of being a nonresponder were
calculated using multivariable unconditional logistic regres-
sion analysis for all SCLC patients as well as in the sub-
groups. The survival time end points in terms of OS and TTP
were evaluated analogously using the Cox proportional haz-
ards model with hazard ratio (HR) estimates and 95% CI. For
the calculation of ORs and HRs, -938AA was the reference
genotype to which we compared the two genotypes CA and
CC separately and in combination.
Furthermore, multivariable regressions and by that the
outcome measures OR and HR were adjusted in general for
clinical stage, chemotherapy regimen, performance status
(Eastern Cooperative Oncology Group [ECOG]), and gender;
when analyzing the two subgroups with extensive and limited
disease, these were adjusted for chemotherapy regimen, per-
formance status (ECOG), and gender only. One-year, 2-year,
and 3-year TTP and OS as well as median TTP and median
OS rates were calculated from the Kaplan-Meier curves, and
the log-rank test was used to assess differences between the
Kaplan-Meier curves.
The genotype frequencies were tested for deviation
from the Hardy-Weinberg equilibrium using the 2 goodness-
of-fit test. All statistical analyses were performed with SAS
software version 9.1.3.
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RESULTS
Of all 188 patients analyzed, 101 showed limited dis-
ease and 87 extensive disease (Table 1). There was 100%
concordance between the newly developed fluorescence-
based melting curve analysis and the restriction fragment
length polymorphism analysis for the 200 samples genotyped
with both methods for the purpose of validation. The BCL-2
-938A-allele was found to have a frequency of 0.53, and
genotypes were in Hardy-Weinberg equilibrium.
Association of Genotypes with Chemotherapy
Response
For the chemotherapeutics used and for further pa-
tients’ characteristics, see Table 1.
The median time interval between baseline scan and
treatment start was 6 days (range, 0–35 days) and between end
of treatment and first restaging was 18 days (range, 5–44 days).
Among all 188 patients, 148 were responders and 40
were nonresponders to first-line chemotherapy. No statisti-
cally significant association of BCL-2 C-938A with chemo-
therapy response was found (Table 2).
Association of Genotypes with TTP and OS
The median TTP was 8.9 months (95% CI  8.1–10.3)
(responders: 9.5 [95% CI  8.2–10.7], nonresponders 7.8
[95% CI 4.8–9.1]). The median OS was 13.3 months (95%
CI  11.5–15.9) (responders: 14.7 [95% CI  11.5–18.5],
nonresponders 11.8 [95% CI  8.8–13.8]).
BCL-2 -938CC had significantly worse TTP compared
with BCL-2 -938AA in all SCLC patients (HR  1.86; 95%
CI  1.10–3.13, p  0.021, CC: median 7.8 months, 95%
CI  5.3–9.8 versus AA: median 10.4 months, 95% CI 
7.8–12.4).
For extensive disease patients and for limited disease
patients, similar but not statistically significant effects were
observed (compare Table 3). The corresponding Kaplan-
Meier curves are shown in Figures 1A–C.
Evaluation of OS showed results similar to TTP. In all
patients with SCLC, BCL-2 -938CC was associated with
worse survival (HR 2.38; 95% CI 1.38–4.12, p 0.002,
CC: median 11.2 months, 95% CI  8.5–14.6 versus AA:
median 14.4 months, 95% CI  12.0–21.9) (Table 4).
This impact could also be shown in patients with
limited disease (HR 2.57; 95% CI 1.18–5.60, p 0.017,
CC: median 14.6 months, 95% CI  11.2–18.3 versus AA:
median 21.2 months, 95% CI  14.1–39.3). In patients with
extensive disease, a similar but statistically not significant
effect was observed (compare Table 4).
The corresponding Kaplan-Meier curves are shown in
Figures 1D–F.
DISCUSSION
To our knowledge, this is the first report in patients with
SCLC, analyzing the association between the BCL-2 C-938A
polymorphism and chemotherapy response and outcome.
In our study, the BCL-2 -938 CC-genotype was found
to be associated with an adverse influence on TTP and OS,
which means that BCL-2 -938AA was shown to be a marker
of improved TTP and OS. These results are somewhat unex-
pected for two reasons. First, the BCL-2 -938A-allele has
been associated with increased BCL-2 expression.8 An in-
crease of the antiapoptotic BCL-2 should lead to a less
favorable chemotherapy response and outcome because of a
reduced ability of tumor cells to undergo apoptosis. Second,
BCL-2 overexpression has been shown to be a marker of
chemotherapy resistance regardless of small and non-small
cell histology.11,12 This resulted in the development of new
promising treatment options for SCLC13 by blocking BCL-2
expression by antisense oligonucleotides.4,14–16
This notion cannot explain our findings in SCLC pa-
tients of a beneficial effect of the BCL-2 AA-genotype.
However, in keeping with our results, BCL-2 overexpression
was previously shown to have a positive influence on survival
in non-small cell lung cancer.17 Conflicting results on the
influence of BCL-2 overexpression on survival in SCLC have
previously been published.18–21 In concordance with our
findings on BCL-2 -938AA and its positive influence on TTP
and OS, the A-allele was also associated with a longer
survival in patients with breast cancer.22 After radical pros-
tatectomy, the BCL-2 CC-genotype leads to earlier recur-
TABLE 1. Patients’ Characteristics
Patients with Small Cell Lung Cancer
Responder
(CR  PR)
(N  148), n (%)
Nonresponder
(SD  PD)
(N  40), n (%)
Gender
Male 108 (73) 33 (83)
Female 40 (27) 7 (18)
Age
60 yr 77 (52) 18 (45)
60 yr 71 (49) 22 (55)
Stage
Limited disease 83 (56) 18 (45)
Extensive disease 65 (44) 22 (55)
Performance status
ECOG 0–1 130 (88) 36 (90)
ECOG 2–3 18 (12) 4 (10)
Chemotherapy regimen
Extensive disease patients
Etoposide and platinum-
based chemotherapy
46 (31) 9 (23)
Etoposide, ifosfamide,
and platinum-based
chemotherapy
1 (0.7) 0 (0)
Other combinations 18 (12) 13 (33)
Limited disease patients
Etoposide and platinum-
based chemotherapy
59 (40) 11 (28)
Etoposide, ifosfamide,
and platinum-based
chemotherapy
11 (7) 3 (8)
Other combinations 13 (9) 4 (10)
Values are given as n (%).
ECOG, Eastern Cooperative Oncology Group; CR, complete remission; PR, partial
remission; SD, stable disease; PD, progressive disease.
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rence,23 and it is also associated with poor prognosis and
lower survival in renal cancer,24 whereas in leukemia pa-
tients, the BCL-2 -938A-allele was associated with worse
survival.8 Interestingly, an increase in BCL-2 copy number in
SCLC cell lines and tumors leading to higher BCL-2 expres-
sion has previously been associated with higher sensitivity to
treatment with BCL-2 antisense oligonucleotides in SCLC
cell lines.25
Taken together, our findings indicate a negative prog-
nostic impact of the BCL-2 -938CC genotype in SCLC,
where progression and survival of patients with SCLC were
strongly associated with this polymorphism.
Because of the fact that this is a retrospective study of
patients who were not part of a uniform clinical trial, the cohort
shows a variety in initial treatment regimes as well as methods
to follow-up chemotherapy response. This is because the retro-
TABLE 2. Chemotherapy Response According to BCL-2 C-938A Polymorphism
Responder (CR  PR)
(N  148), n (%)
Nonresponder (SD  PD)
(N  40), n (%) OR 95% CI p
All patients with small cell lung cancer
AA (reference) 37 (25) 10 (25) 1
CA 86 (58) 21 (53) 0.78b 0.33–1.87 0.575
CC 25 (17) 9 (23) 1.08b 0.36–3.24 0.887
CA  CCa 111 (75) 30 (75) 0.84b 0.36–1.95 0.690
Patients with extensive disease
AA (reference) 14 (10) 5 (13) 1
CA 40 (27) 10 (25) 0.57c 0.15–2.16 0.411
CC 11 (7) 7 (18) 1.56c 0.33–7.27 0.573
CA  CCa 51 (35) 17 (43) 0.75c 0.22–2.65 0.660
Patients with limited disease
AA (reference) 23 (16) 5 (13) 1
CA 46 (31) 11 (28) 1.06c 0.3–3.49 0.918
CC 14 (10) 2 (5) 0.75c 0.12–4.70 0.756
CA  CCa 60 (41) 13 (33) 1.00c 0.32–3.20 0.995
a CA  CC  C-allele carriers.
b Adjusted for clinical stage, chemotherapy regimen, performance status (ECOG), and gender.
c Adjusted for chemotherapy regimen, performance status (ECOG), and gender.
ECOG, Eastern Cooperative Oncology Group; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; OR, odds ratio; CI, confidence interval.
TABLE 3. Time to Progression According to BCL-2 C-938A Polymorphism
n HR
95% CI
(from) p
1-yr
TTP (%) 95% CI
2-yr
TTP (%) 95% CI
3-yr
TTP (%) 95% CI
Median
TTP (mo) 95% CI
All patients with small cell
lung cancer
AA (reference) 47 1 35 20–50 16 6–31 6 1–22 10.4 7.8–12.4
CA 107 0.96a 0.64–1.46 0.860 31 21–41 9 4–17 9 4–17 8.9 7.6–10.8
CC 34 1.86a 1.10–3.13 0.021 17 6–33 0 — 0 — 7.8 5.3–9.8
CA  CCb 141 1.10a 0.74–1.63 0.644 27 19–36 7 3–13 7 3–13 8.8 7.6–9.8
Patients with extensive
disease
AA (reference) 19 1 13 2–34 0 — 0 — 6.2 4.8–8.9
CA 40 0.65c 0.34–1.22 0.179 20 9–35 3 0.3–15 0 — 6.9 5.5–8.7
CC 18 1.49c 0.69–3.21 0.316 0 — 0 — 0 — 5.0 3.1–7.8
CA  CCb 68 0.77c 0.42–1.42 0.400 15 6–27 2 0.2–11 0 — 6.5 5.2–7.8
Patients with limited disease
AA (reference) 28 1 49 27–68 28 10–48 10 1–34 11.6 10.2–21.3
CA 57 1.42c 0.81–2.52 0.225 39 26–52 14 6–25 14 6–25 10.9 9.1–12.4
CC 16 2.01c 0.96–4.20 0.063 32 11–56 0 — 0 — 13.3 6.8–12.1
CA  CCb 73 1.53c 0.88–2.65 0.130 37 26–49 11 5–20 11 5–20 10.7 9.4–11.9
Values in bold indicate HR estimates with p  0.05.
a Adjusted for clinical stage, chemotherapy regimen, ECOG, and gender.
b CA  CC  C-allele carriers.
c Adjusted for chemotherapy regimen, ECOG, and gender.
CI, confidence interval; TTP, time to progression; ECOG, Eastern Cooperative Oncology Group.
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spective study design did not allow the possibility of influencing
the given clinical process. On the one hand, the cohort therefore
is not an artificial construct and reflects the heterogeneity in the
population of patients with SCLC. On the other hand, this
variety could lead to imbalances that might bias the results of the
study. We tried to avoid bias by adjusting for clinical stage,
chemotherapy regimen, performance status (ECOG), and gender
in the statistical analysis.
FIGURE 1. Time to progression (TTP) and overall survival (OS) for BCL-2 C-938A with number of subjects at risk. TTP in all
patients with small cell lung cancer (A), in patients with extensive disease (B), and in patients with limited disease (C). OS in
all patients with small cell lung cancer (D), in patients with extensive disease (E), and in patients with limited disease (F).
Journal of Thoracic Oncology • Volume 6, Number 1, January 2011 Apoptotic Pathway Gene BCL-2 and Survival in SCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 187
However, because of the retrospective character of the
study, the results can merely be hypothesis generating. The
results need to be confirmed in a prospective trial using a
multivariate analysis to verify BCL-2 C-938A as a marker of
survival and TTP in patients with SCLC. Particularly, it
would be interesting to evaluate the association of BCL-2
C-938A genotypes with the effect of BCL-2 antisense treat-
ment in SCLC patients.
We did not find significant results for chemotherapy
response despite the fact that there were significant effects for
TTP and OS. This might be due to the fact that tumor
progression and death of a group of patients are harder end
points than response to chemotherapy, e.g., because it is
difficult to distinguish tumor from necrosis or atelectasis by
CT.26 In addition, only 24 pairs of CT scans were available to
follow-up chemotherapy response. The rest of the patients
were followed up by chest radiograph. This makes the data on
chemotherapy response more heterogeneous and less reliable.
Another factor could be that response as categorical outcome
has less statistical power than the quantitative end points TTP
and OS. Alternatively, the results could reflect a limited
association of the early response outcome determined in this
study and the two survival end points.
The observed negative effects were only seen for homozy-
gous carriers of the C-allele and not for all C-allele carriers. This
may suggest a recessive effect of the C-allele. The results in the
subgroup of patients with extensive disease and in the subgroup
of patients with limited disease reflect the results in the main
group of all patients with SCLC. The results point in the same
direction as in the main group but significance is not always
reached. This could be due to the lower case numbers in these
subgroups. Another factor that needs to be critically assessed
is the fact that the number of CC-allele carriers was not
evenly distributed among the two stage groups. In the group
of patients with extensive disease stage, 18 patients carried
the CC genotype. This reflects 21% of all patients with
extensive disease stage. In the group of patients with limited
disease stage, 16 patients carried the CC genotype. This
reflects 16% of all patients with limited disease stage. Be-
cause extensive disease stage patients have a known worse
outcome, the imbalance of the genotypes by stage could
contribute to the observed worse outcome for the CC geno-
type in the group as a whole.
One advantage of our study is that we investigated a
genetic polymorphism as a host factor in DNA derived from
peripheral blood lymphocytes. This can be easily and nonin-
vasively obtained and analyzed within a short time frame,
making it ideal for routine clinical use. However, we are
aware that the measured host factor does not necessarily
reflect the situation in a given tumor, where clonal transfor-
mation might have occurred. One hundred forty of 188
patients were treated with a standard regimen of platinum-
based therapy in combination with etoposide. Thus, the re-
maining treatment group, receiving different drug combina-
tions, mostly adriamycin/cyclophosphamide/vincristine, is
too small to differentiate in both subgroups a predictive
impact of the polymorphism on outcome. However, all pa-
tients received chemotherapy and mostly a combination of
platinum-based treatment and etoposide. In the overall group
receiving chemotherapy, BCL-2 -938CC indicates inferior
outcome in terms of TTP and OS. A prospective study design
with different therapy regimen subgroups would provide an
TABLE 4. Overall Survival According to BCL-2 C-938A Polymorphism
n HR
95% CI
(from) p
1-yr
OS (%) 95% CI
2-yr
OS (%) 95% CI
3-yr
OS (%) 95% CI
Median
OS (mo) 95% CI
All small cell lung cancer
patients
AA (reference) 47 1 68 52–80 33 19–49 23 11–39 14.4 12.0–21.9
CA 107 1.14a 0.74–1.76 0.543 54 44–63 29 19–39 9 4–18 13.3 11.4–18.5
CC 34 2.38a 1.38–4.12 0.002 42 24–59 9 2–24 0 — 11.2 8.5–14.6
CA  CCb 141 1.30a 0.85–1.97 0.223 51 42–60 24 17–33 7 3–14 12.2 11.3–15.9
Patients with extensive
disease
AA (reference) 19 1 39 18–60 13 2–34 7 0.4–25 10.5 5.8–14.5
CA 40 0.89c 0.48–1.65 0.710 34 21–48 19 9–32 0 — 10.1 9.0–11.8
CC 18 1.95c 0.89–4.30 0.097 14 1–42 0 — 0 — 7.5 5.0–10.2
CA  CCb 68 1.01c 0.56–1.84 0.968 29 18–42 15 7–26 0 — 9.4 8.3–11.3
Patients with limited
disease
AA (reference) 28 1 91 68–98 49 26–69 37 16–58 21.2 14.1–39.3
CA 57 1.32c 0.72–2.44 0.372 71 56–81 38 23–52 16 7–30 20.6 15.9–25.5
CC 16 2.57c 1.18–5.60 0.017 67 38–85 16 3–39 0 — 14.6 11.2–18.3
CA  CCb 73 1.51c 0.84–2.72 0.167 70 57–79 33 21–45 12 5–23 18.5 14.6–23.2
Values in bold indicate HR estimates with p  0.05.
a Adjusted for clinical stage, chemotherapy regimen, ECOG and gender.
b CA  CC  C-allele carriers.
c Adjusted for chemotherapy regimen, ECOG, and gender.
CI, confidence interval; OS, overall survival; HR, hazard ratio.
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opportunity to elucidate the predictive value of the investi-
gated polymorphisms.
In conclusion, this is the first study to our knowledge
that revealed statistically significant associations for BCL-2
C-938A, and TTP as well as OS in SCLC patients, indicating
a negative prognostic impact of the BCL-2 -938CC genotype.
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